Use of allopurinol for the treatment of palmar plantar erythrodysesthesia

• US 8,557,829 B2
• Filed: 05/24/2011
• Issued: 10/15/2013
• Est. Priority Date: 06/01/2006
• Status: Expired due to Fees

• Current Assignee: Nobera Pharma, S.L.
• Original Assignee: Nobera Pharma, S.L.
• Inventors: Rodemer, Yolanda
• Primary Examiner(s): Gembeh, Shirley V
• Application Number:
  US13/114,768
• Publication Number:
  US 20110224237A1
• Time in Patent Office: 875 Days
• Field of Search: 514/262.1
• US Class Current: 514/262.1
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/16 Emollients or protectives, e.g. against radiation
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Use of allopurinol or a pharmaceutically acceptable salt thereof for the treatment or prevention of palmar plantar erythrodysesthesia induced by chemotherapy. The allopurinol or its salt is administered topically to the affected areas, palms and soles, preferably in the form of a cream.

Claims

1. A pharmaceutical composition for topical administration to the skin of a subject to treat chemotherapy-induced palmar plantar erythrodysesthesia (PPE) (hand and foot syndrome), comprising 1-10% by weight of the pharmaceutical composition of allopurinol or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is formulated for topical administration to the skin of a subject, and is free of methylsulfonylmethane or cetomacrogol.

2. The pharmaceutical composition of claim 1, comprising about 1-8% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition of claim 2, comprising about 1-5% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

4. The pharmaceutical composition of claim 3, comprising about 2-4% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

5. The pharmaceutical composition of claim 1, further comprising pyridoxine.

6. The pharmaceutical composition of claim 1, in the form of a hydrophylic cream.

7. The pharmaceutical composition of claim 1, in the form of a cream.

8. A pharmaceutical composition for topical administration to the skin of a subject to treat chemotherapy-induced palmar plantar erythrodysesthesia (PPE) (hand and foot syndrome), comprising 1-10% by weight of the pharmaceutical composition of allopurinol or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is formulated for topical administration to the skin of a subject, and is free of methylsulfonylmethane and cetomacrogol.

9. The pharmaceutical composition according to claim 8, additionally comprising pyridoxine.

10. The pharmaceutical composition according to claim 8, in the form of a cream.

11. The pharmaceutical composition according to claim 8, in the form of a hydrophilic cream.

12. The pharmaceutical composition according to claim 8, comprising from about 1-8% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical composition according to claim 12, comprising from about 1-5% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

14. The pharmaceutical composition according to claim 13, comprising from about 2-4% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition according to claim 8, comprising about 3% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical composition according to claim 15, additionally comprising pyridoxine.

17. The pharmaceutical composition according to claim 15, in the form of a cream.

18. The pharmaceutical composition according to claim 15, in the form of a hydrophilic cream.

19. The pharmaceutical composition according to claim 8, comprising about 8% by weight of the pharmaceutical composition of allopurinol or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition according to claim 19, additionally comprising pyridoxine.

21. A pharmaceutical composition according to claim 19, in the form of a cream.

22. A pharmaceutical composition according to claim 19, in the form of a hydrophilic cream.